ArticleJournal of proteins and proteomics2021
Structure-based inhibitor screening of natural products against NSP15 of SARS-CoV-2 revealed thymopentin and oleuropein as potent inhibitors.
Article in Journal of proteins and proteomics, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed, 1 synthesis or guideline pooled it, 0 citations in OpenAlex.
- Olive Leaves as a Potential Phytotherapy in the Treatment of COVID-19 Disease; A Mini-Review.Frontiers in pharmacology · 2022Pooled it
- Advancements in the development of antivirals against SARS-Coronavirus.Frontiers in cellular and infection microbiology · 2025Review
- Article
- Targeting Ribonucleases with Small Molecules and Bifunctional Molecules.ACS chemical biology · 2023Review
- Plausibility of natural immunomodulators in the treatment of COVID-19-A comprehensive analysis and future recommendations.Heliyon · 2023Review
- Review
- Oleuropein as a Potent Compound against Neurological Complications Linked with COVID-19: A Computational Biology Approach.Entropy (Basel, Switzerland) · 2022Article
- Chemical system biology approach to identify multi-targeting FDA inhibitors for treating COVID-19 and associated health complications.Journal of biomolecular structure & dynamics · 2022Article
- Current status of structure-based drug repurposing against COVID-19 by targeting SARS-CoV-2 proteins.Biophysics and physicobiology · 2021Article
- Pathogen effects on the brain: the case of SARS-CoV-2 spike protein and neuro COVID.Frontiers in neurologyReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Coronaviruses are enveloped, non-segmented positive-sense RNA viruses with the largest genome among RNA viruses. Their genome contains a large replicase ORF which encodes nonstructural proteins (NSPs), structural, and accessory genes. NSP15 is a nidoviral RNA uridylate-specific endoribonuclease (NendoU) with C-terminal catalytic domain. The endoribonuclease activity of NSP15 interferes with the innate immune response of the host. Here, we screened Selleckchem Natural product database of the compounds against NSP15, and we found that thymopentin and oleuropein displayed highest binding energies. The binding of these molecules was further validated by molecular dynamic simulations that revealed them as very stable complexes. These drugs might serve as effective counter molecules in the reduction of virulence of this virus; may be more effective if treated in combination with replicase inhibitors. Future validation of both these inhibitors is worth the consideration for patients being treated for COVID-19. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s42485-021-00059-w.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.